‘The journey from university spin-out to Nasdaq’
This time we are pleased to welcome Hans Schambye, CEO of Galecto Inc. and Chairman of Dansk Biotek. Hans will enlighten the audience about how Galecto went from being a small, university spin-out company, micro-financed by European VCs in the aftermath of the financial crisis, to today, where Galecto is a clinical-stage company incorporated in the U.S and listed on Nasdaq.
Furthermore, he will highlight how the team behind Galecto has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme and how both influence biological pathways of complex and devastating diseases, including fibrosis, inflammation and cancer.
Program of the day
15.30 Doors open
16.00 Introduction to BII and the subject of the day: Bobby Soni, Chief Business Officer at BII
16.10 Keynote speaker: Hans Schambye ‘The journey from university spin-out to Nasdaq’
16.40 Fireside chat with Bobby Soni and questions
17.00 Informal networking and closing reception
Please note that the event has free admittance with 70 tickets available. Please sign up quickly to secure your seat.
If you have registered for the event but cannot attend, please email Tina Chanruk Larsen.
About Hans Schambye:
Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. He is the CEO of Galecto Inc., Chairman of Dansk Biotek and board member at BII.
Previously, he served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has also served as chairman or director of several biotech companies, including IO Biotech, Forward Pharma and Step Pharma SA
Hans co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company that Maxygen acquired in 2000. Before this he had a successful research career at Stanford University and Copenhagen University within receptor biology.
He holds a master’s degree from University of Southern Denmark and a Ph.D. in Molecular Pharmacology from Copenhagen University.
About Talks at the Square:
Talks at the Square’ is an event series launched by BII in 2019 with a key focus on spreading ideas and knowledge in life science entrepreneurship to inspire researchers to bring science out of the lab and into the economy. The events feature high-level international speakers with topics that emphasize innovations and inspirational topics within bioindustrials, health tech, and therapeutics. Talks are hosted on the Square at the BII facilities in Copenhagen Bio Science Park in Copenhagen.
Read more about Talks at the Square